Similar to these breast cancer examples, in chronic myelogenous leukemias, Imatinib treatment can result in hyperactivation of SRC family kinases such as LYN (v-yes-1 Yamaguchi sarcoma viral related oncogene homolog), as well as other kinases such as MEK, ERK, IKKα (IκB kinase α), PKCβ (protein kinase C beta), and NEK9, ultimately rendering these BCR-ABL-driven cancers unresponsive to Imatinib (34). Here, MAP2K7 is linked to cancer.